Skip to main content

Table 1 Baseline characteristics of a cohort of 91 HIV-infected infants followed up at Baylor-Uganda

From: Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda

Variable Median (IQR) N (%)
Age (months) 6.2 (4.04-9.0)  
 0-6   43 (47.3)
 7-12   48 (52.7)
Sex   
 Male   38 (41.8)
 Female   53 (58.2)
CD4 Percent 20 (15-29)  
Viral load (copies/ml)   
 <100,000   14 (18.2)
 100,000-750,000   29 (37.7)
 >750,000   34 (44.1)
WHO clinical stage   
 1   13 (14.4)
 2   27 (30.0)
 3   32 (35.6)
 4   18 (20.0)
ART regimen   
 ZDV+3TC+NVP   14 (16.7)
 ZDV+3TC+Lop/r   13 (15.5)
 D4T+3TC+NVP   30 (35.7)
 D4T+3TC+Lop/r   16 (19.0)
 Other   11 (13.1)
Weight/Age z-score   
 Median (IQR) −2.2 (-3.89 - -1)  
 <-3SD score   33 (36.3)
 ≥-3SD to <-2SD   24 (26.4)
 ≥-2≤SD to < -1SD   11 (12.1)
 ≥-1SD   23 (25.2)
Height/Age z-score   
 Median −1.92 (-3.05 - -1.02)  
 <-3SD score   23 (25.3)
 ≥-3SD to<-2SD   20 (21.9)
 ≥-2SD to<-1SD   26 (28.6)
 ≥-1SD   22 (24.2)
  1. IQR= Inter-quartile range, SD= standard deviation, WHO= World Health Organization, ART=antiretroviral therapy, ZDV=zidovudine, 3TC=lamivudine, D4T=stavudine, NVP=nevirapine, Lop/r= Lopinavir/ritonavir.
\